Kite Pharma Inc (KITE)

179.79
0.02 0.01
Prev Close 179.81
Open 179.82
Day Low/High 179.55 / 179.95
52 Wk Low/High 39.82 / 179.95
Volume 3.76M
Avg Volume 2.18M
Exchange
Shares Outstanding 57.36M
Market Cap 10.31B
EPS -5.50
Div & Yield N.A. (N.A)

Latest News

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Gilead Has Trouble Written All Over It

Gilead Has Trouble Written All Over It

Getting back into an uptrend will be a challenge for GILD.

3 Biotech Stalwarts Just Can't Bio a Break

3 Biotech Stalwarts Just Can't Bio a Break

The stocks of Amgen, Celgene and Gilead Sciences all took hits after posting quarterly results.

Why Is Flexion Falling, and Other Questions

Why Is Flexion Falling, and Other Questions

The first part of Flexion's decline can be attributed to some profit taking.

Getting Bullish on Gilead

Getting Bullish on Gilead

I'm setting up a risk reversal to either buy the stock lower or participate in the upside.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

That would mean that there is the chance for a comeback here of some note.

Wedbush Upgrades Kite Pharma to Neutral

Bears Still Can't Execute in the 'Red Zone'

Bears Still Can't Execute in the 'Red Zone'

Monday's action failed to change the overall character of the market

My Takeaways and Observations

"Yeah, well, that's just, like, your opinion, man." -- The Dude, The Big Lebowski Strikes and gutters today -- in a market characterized by winners and losers and weakening breadth. Ups and downs.    Amazon's shares may be signaling there is no fun,...

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

This market is focused on Apple and Gilead's planned acquisition of Kite.

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending stocks

Gilead's Gain on Kite Acquisition Doesn't Make Sense

For the life of me I don't see why Gilead Sciences'  shares should respond very positively to the $13 billion acquisition of Kite Pharmaceutical . On Fast Money it is being argued that the takeover is anti-dilutive against cash. So what? It signals ...

Midday Report: Stocks Mixed as Hurricane Harvey Damage Assessed

Midday Report: Stocks Mixed as Hurricane Harvey Damage Assessed

Stocks are mixed.

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Gilead is acquiring Kite Pharma.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Kite Pharmaceutical Is Flying High

Kite Pharmaceutical Is Flying High

This stock has barely had a pullback.

Rev's Forum: Don't Underestimate the Power of a Plodding Market

Rev's Forum: Don't Underestimate the Power of a Plodding Market

The best move has been to simply stick with the trend.